STAGE 1 & 2 HYPERTENSION

本研究的主要目的是通过测量1期和2期高血压患者出现和恶化的不良事件，提供1.5mg每日一次（QD） SR莫昔定的长期安全性数据（长达12个月）。次要目的是确定SR莫昔定对坐姿舒张压基线变化的影响。坐位舒张压波谷反应率（降低大于等于10mmhg或终点< 90mmhg）。其他血压：收缩压（坐、仰卧、站立和站立2分钟）舒张压（仰卧、站立和站立2分钟）心率（坐、仰卧、站立和站立2分钟）。

The primary objective of this study is to provide long-term safety data (up to 12 months) on 1.5mg once daily(QD) SR moxonidine as measured by emerging and worsening adverse events in Stage 1 and Stage 2 hypertensive patients. The secondary objectives are to determine the effect of SR moxonidine on: The change from baseline in sitting diastolic blood pressure measured at trough. Sitting diastolic blood pressure responder rate at trough (reduction of greater than and equal to 10 mm Hg or endpoint of <90 mm Hg). Other blood pressures: Systolic (sitting, supine, standing, and standing 2 minutes) Diastolic (supine, standing, and standing 2 minutes) Heart rate (sitting, supine, standing, and standing 2 minutes).